Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire

Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire

Background: Elexacaftor–tezacaftor–ivacaftor (ETI) is a novel, highly effective CFTR modulator combination proven to enhance lung function and body weight in people with cystic fibrosis (pwCF) carrying a F508del mutation. Recently, we revealed significant reductions in abdominal symptoms (AS) in Ger...

Full description

Bibliographic Details
Main Authors: Jochen G. Mainz, Anton Barucha, Pu Huang, Lilith Bechinger, Franziska Duckstein, Louise Polte, Pauline Sadrieh, Lutz Nährlich, Olaf Eickmeier, Suzanne Van Dullemen, Patience Eschenhagen, Carsten Schwarz, Stefan Lüth, Carlos Zagoya, Ute Graepler-Mainka
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Pharmacology
Subjects:
gastrointestinal
patient-reported outcome measure
prospective
symptom score
diary
CFAbd-Score
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1167407/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1167407/full

Similar Items